VEGF Inhibition for Cancer Therapy

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 • 10,779 citations

Tumor Angiogenesis: Therapeutic Implications

1971 • 9,898 citations

The biology of VEGF and its receptors

2003 • 9,272 citations

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

1992 • 4,631 citations

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

1996 • 4,143 citations

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

1995 • 3,977 citations

Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid

1983 • 3,942 citations

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

1996 • 3,664 citations

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

2003 • 2,723 citations

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

1995 • 2,650 citations

Transplacental Carcinogenesis by Stilbestrol

1971 • 2,595 citations

Regulation of angiogenesis by hypoxia: role of the HIF system

2003 • 2,404 citations

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

1989 • 2,267 citations

The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor

1992 • 2,042 citations

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

1993 • 1,961 citations

Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

2002 • 1,699 citations

ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS

1971 • 1,643 citations

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

2005 • 1,630 citations

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

1992 • 1,528 citations

VEGF and the quest for tumour angiogenesis factors

2002 • 1,467 citations

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

2005 • 1,303 citations

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

2005 • 1,140 citations

HIF-1 and mechanisms of hypoxia sensing

2001 • 1,131 citations

Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial

2005 • 923 citations

Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium.

1993 • 764 citations

A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.

1986 • 641 citations

Vascular Endothelial Growth Factor as a Target for Anticancer Therapy

2004 • 564 citations

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

2005 • 523 citations

Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.

1990 • 503 citations

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

2003 • 491 citations

Vasculae Reactions of Normal and Malignant Tissues in Vivo. I. Vascular Reactions of Mice to Wounds and to Normal and Neoplastic Transplants

1945 • 466 citations

Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599

2005 • 364 citations

Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

2005 • 358 citations

High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200

2005 • 347 citations

Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas

2005 • 246 citations

Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber

1939 • 232 citations

THE JOHNS HOPKINS HOSPITAL BULLETIN

1890 • 231 citations

Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective.

2005 • 230 citations

A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1)

2005 • 203 citations

Expression of vascular endothelial growth factor, hypoxia inducible factor 1α, and carbonic anhydrase IX in human tumours

2004 • 156 citations

Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis.

2004 • 155 citations

Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC)

2005 • 120 citations

Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

2005 • 100 citations

Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy

2005 • 96 citations

A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome.

1990 • 96 citations

First-line treatment for advanced non-small-cell lung cancer.

2005 • 34 citations

Bevacizumab, when Added to Paclitaxel/Carboplatin, Prolongs Survival in Previously Untreated Patients with Advanced Non–Small-Cell Lung Cancer: Preliminary Results from the ECOG 4599 Trial

2005 • 32 citations

Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy

2005 • 18 citations